Spinal cord injury-induced immude deficiency Syndrome: Natuarl killer (NK) cell functionality after spinal cord injury

Spinal cord injury-induced immude deficiency Syndrome: Natuarl killer (NK) cell functionality after spinal cord injury - SCI-IDS: NK cells function

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00009855

Enrollment

Registered

2016-01-13

Start date

2012-10-17

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G82

Interventions

Group 1: i) Traumatic spinal cord injury (AIS A-D): Th5 and above

Each Patient will receive a blood withdrawal at day 5-7, 11-28 and at week 8-12 after the lesion. The NK cell function including cytotoxicity (CD107a Expression) and production of immunmodulatory cyto

Group 3: iii) Spinal Fracture

Group 4: iv) Healthy controls

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Patients with acute isolated spinal cord injury (AIS A-D) planned for surgical stabilization and decompression, lesion may include more than 1 segment - Patients with acute isolated spinal fracture planned for surgical stabilization, lesion may include more than 1 segment - = 2 spinal cord or vertebral lesions definable one from another - Documented informed consent of the patient

Exclusion criteria

Exclusion criteria: - Non-traumatic spinal cord injury - 2 or more spinal cord or vertebral lesions definable one from another - Severe polytrauma (definition: patients with severe injuries of life-sustaining organ systems, which per se and in the acute phase are life-threatening (e.g., severe pelvic trauma, severe body cavity injuries) - Concomitant traumatic brain injury (TBI) (definition: i) Patients with persisting neurological deficit in consequence of the TBI, ii) patient with severe TBI (Glasgow Coma Scale = 8), and iii) patients with intracranial pressure monitoring sensors.) - Neoplasia and/or antineoplastic therapy - Rheumatic disease, collagenosis, vasculitis or other autoimmune disease - Preexisting chronic infectious disease (before the injury) - Preexisting systemic steroid treatment - Severe alcohol or drug addiction - Pregnancy, lactation

Design outcomes

Primary

Measure	Time frame
NK cell cytotoxicity (CD107a Expression) nach PMA/ionomycin through Flow Cytometry (FACS) 10 weeks after SCI	—

Secondary

Measure	Time frame
NK cell cytokine (IFN-gamma and TNF-alpha) production after PMA/ionomycin Stimulation through flow cytometry (FACS) 10 weeks after SCI	—

Countries

Germany

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 12, 2026